Despite these promising data, xerostomia (dry mouth) remains an important quality-of-life toxicity that can be severe and dose-limiting, especially in patients treated with alpha-emitting PSMA-TRT [1, 9, 10]. This evidence concerns the gene FOLH1 and xerostomia.